Tags

Type your tag names separated by a space and hit enter

Long-term effects of micronized Alloderm injection for unilateral vocal fold paralysis.
Laryngoscope. 2005 Sep; 115(9):1691-6.L

Abstract

OBJECTIVES

Micronized Alloderm (Cymetra) is a relatively new product used for vocal fold augmentation. Previous studies evaluating possible long-term effectiveness of this product have shown mixed results. The objective of this present study is to reassess possible long-term results of Cymetra injection laryngoplasty in patients with unilateral true vocal fold paralysis.

STUDY DESIGN

Retrospective review of patients with unilateral true vocal fold paralysis who received Cymetra injection laryngoplasty between March 2001 and March 2004.

METHODS

Preoperative voice samples and videostroboscopic findings were compared with the most recently available postoperative data to assess efficacy of the procedure. A panel of voice experts analyzed both vocal and vibratory function in these samples. In addition, pre- and postoperative voice-related quality of life measures and patients' self-ratings of voice outcomes were compared.

RESULTS

Twenty patients (7 male, 13 female; 14 with left-sided paralysis, 6 with right-sided paralysis) were identified in the study population. Cymetra injection was performed an average of 45.1 months after onset of vocal fold paralysis (range -216 months), and average follow-up postinjection was 11.2 (range -35) months. Comparing pre- and postoperative measures, voice quality (P < .0001), glottal closure (P < .0001), and degree of vocal fold bowing (P < .0001) were all improved by injection. Quality of life measures and patients' self-perceptions of vocal quality were also improved (P < .01). Fifteen (75%) patients showed long-lasting results. Eight patients showed improvement for more than 12 months after injection.

CONCLUSION

Cymetra injection laryngoplasty offers improved vocal and vibratory function to patients with unilateral true vocal fold paralysis. The benefits of such medialization may be longer lasting than previously reported, and further long-term study is warranted.

Authors+Show Affiliations

The Voice Center, Head and Neck Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A71, Cleveland, OH 44195, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16148719

Citation

Milstein, Claudio F., et al. "Long-term Effects of Micronized Alloderm Injection for Unilateral Vocal Fold Paralysis." The Laryngoscope, vol. 115, no. 9, 2005, pp. 1691-6.
Milstein CF, Akst LM, Hicks MD, et al. Long-term effects of micronized Alloderm injection for unilateral vocal fold paralysis. Laryngoscope. 2005;115(9):1691-6.
Milstein, C. F., Akst, L. M., Hicks, M. D., Abelson, T. I., & Strome, M. (2005). Long-term effects of micronized Alloderm injection for unilateral vocal fold paralysis. The Laryngoscope, 115(9), 1691-6.
Milstein CF, et al. Long-term Effects of Micronized Alloderm Injection for Unilateral Vocal Fold Paralysis. Laryngoscope. 2005;115(9):1691-6. PubMed PMID: 16148719.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term effects of micronized Alloderm injection for unilateral vocal fold paralysis. AU - Milstein,Claudio F, AU - Akst,Lee M, AU - Hicks,M Douglas, AU - Abelson,Tom I, AU - Strome,Marshall, PY - 2005/9/9/pubmed PY - 2005/11/3/medline PY - 2005/9/9/entrez SP - 1691 EP - 6 JF - The Laryngoscope JO - Laryngoscope VL - 115 IS - 9 N2 - OBJECTIVES: Micronized Alloderm (Cymetra) is a relatively new product used for vocal fold augmentation. Previous studies evaluating possible long-term effectiveness of this product have shown mixed results. The objective of this present study is to reassess possible long-term results of Cymetra injection laryngoplasty in patients with unilateral true vocal fold paralysis. STUDY DESIGN: Retrospective review of patients with unilateral true vocal fold paralysis who received Cymetra injection laryngoplasty between March 2001 and March 2004. METHODS: Preoperative voice samples and videostroboscopic findings were compared with the most recently available postoperative data to assess efficacy of the procedure. A panel of voice experts analyzed both vocal and vibratory function in these samples. In addition, pre- and postoperative voice-related quality of life measures and patients' self-ratings of voice outcomes were compared. RESULTS: Twenty patients (7 male, 13 female; 14 with left-sided paralysis, 6 with right-sided paralysis) were identified in the study population. Cymetra injection was performed an average of 45.1 months after onset of vocal fold paralysis (range -216 months), and average follow-up postinjection was 11.2 (range -35) months. Comparing pre- and postoperative measures, voice quality (P < .0001), glottal closure (P < .0001), and degree of vocal fold bowing (P < .0001) were all improved by injection. Quality of life measures and patients' self-perceptions of vocal quality were also improved (P < .01). Fifteen (75%) patients showed long-lasting results. Eight patients showed improvement for more than 12 months after injection. CONCLUSION: Cymetra injection laryngoplasty offers improved vocal and vibratory function to patients with unilateral true vocal fold paralysis. The benefits of such medialization may be longer lasting than previously reported, and further long-term study is warranted. SN - 0023-852X UR - https://www.unboundmedicine.com/medline/citation/16148719/Long_term_effects_of_micronized_Alloderm_injection_for_unilateral_vocal_fold_paralysis_ L2 - https://doi.org/10.1097/01.mlg.0000173163.07828.30 DB - PRIME DP - Unbound Medicine ER -